Biological Trace Element Research

, Volume 75, Issue 1, pp 53–63

Preliminary study of combination therapy with interferon-α and zinc in chronic hepatitis C patients with genotype 1b

Authors

  • Takeaki Nagamine
    • Department of Health ScienceGunma University School of Medicine
  • Hitoshi Takagi
    • First Department of Internal MedicineGunma University School of Medicine
  • Hisashi Takayama
    • First Department of Internal MedicineGunma University School of Medicine
  • Akira Kojima
    • First Department of Internal MedicineGunma University School of Medicine
  • Satoru Kakizaki
    • First Department of Internal MedicineGunma University School of Medicine
  • Masatomo Mori
    • First Department of Internal MedicineGunma University School of Medicine
  • Katuyuki Nakajima
    • Otsuka America Pharmaceutical, Inc.
Article

DOI: 10.1385/BTER:75:1-3:53

Cite this article as:
Nagamine, T., Takagi, H., Takayama, H. et al. Biol Trace Elem Res (2000) 75: 53. doi:10.1385/BTER:75:1-3:53

Abstract

We have evaluated the efficacy of interferon-α (IFN-α) plus zinc therapy in hepatitis C patients with genotype 1b, poor responders for IFN alone. Ten patients were injected with 10 MU of IFN-α every day for 4 wk, followed by three times a week for 20 wk (control group). Nine patients took 300 mg of zinc sulfate a day orally during IFN-α therapy (zinc sulfate group), and 15 patients took IFN-α and 150 mg of polaprezinc (polaprezinc group).

On the d 8 of IFN therapy, circadian zinc levels in serum elevated significantly in the polaprezinc group compared to the zinc sulfate group or control group. Serum ALT levels normalized in 73.3% of the polaprezinc group, 55.6% of the zinc sulfate group, and 40.0% of the control group at 6 mo after the end of IFN therapy. Sustained eradication for the hepatitis C virus RNA judged at the end of the 6-mo follow-up period was higher in the polaprezinc group than in the zinc sulfate group (53.3% vs 11.1%, p<0.05) or the control group (20.0%). No clinical side effects of zinc were observed at the dose used. The data suggest that polaprezinc is expected to increase the therapeutic response of IFN-α for chronic hepatitis C with genotype 1b.

Index Entries

Chronic hepatitis C polaprezinc interferon-α HCV RNA

Copyright information

© Humana Press Inc 2000